Abstract-Enzyme replacement therapy (ERT) has improved the quality of life in patients with Gaucher disease (GD). An emerging concern is whether ERT can also halt the neurologic progression in type 3 GD. The authors examined the auditory brainstem response (ABR) in eight children with type 3 GD undergoing high-dose ERT and found a consistent deterioration in ABR response. They conclude that ERT does not halt brainstem degeneration and that alternative therapies must be sought.
However, the success of ERT in neuronopathic disease is uncertain. In GD2, some systemic correction can be achieved, but neurologic demise remains relentless despite high-dose ERT. 3 Because of the inherently slow progression of neurologic signs in GD3, it has not been possible yet to determine the efficacy of ERT. In a recent study of 21 GD3 patients (8 months to 35 years) undergoing ERT, 5 11 patients were reported with normal ABRs, of which only 2 showed deterioration. Of the remaining 10 with abnormal ABRs, there was no deterioration, and 2 even showed improvement, leading to the conclusion that most patients did not deteriorate neurologically under ERT. This has been reinforced by a claim of improvement, including ABR, in a 20-year-old GD3 patient following 1 year of ERT therapy. 6 In contrast, we demonstrate deterioration in the ABRs of eight GD3 children who were on high-dose ERT.
Methods. Subjects. Of the GD3 patients known to us, only 8 of 13 have undergone serial ABRs. Of the 5 of 13 cases that we did not include, 2 children had received bone marrow transplants and were not receiving ERT, 2 children were uncooperative with the ABR recording and we were unable to complete testing, and the remaining patient had died. All eight patients (2 boys, 1 to 13 years old) have been enzymatically diagnosed with GD and subsequently genotyped (table) . Neuronopathic disease was identified by the recording of abnormal saccadic eye movements. 1 All patients (Cases 1 to 8) had been receiving high-dose ERT (120 IU/ kg/2 weeks) for 1 to 3 years. Each of the patients had a significant improvement in their overall systemic response, with no overt neurologic changes observed during this study.
All subjects had standard baseline audiologic assessment including pure tone audiometry (to assess hearing thresholds), tympanometry (to assess middle ear function), otoacoustic emissions (to assess outer hair cell/cochlear function), and ABR (to assess integrity of the auditory pathway in the brainstem). 2 The initial ABR test and audiometry were carried out after commencement of ERT, and the follow-up ABR test and audiometry were carried out 1 to 3 years later (see the table) .
ABR recording. The ABRs were recorded to clicks (100 microseconds in duration) of alternating polarity presented at a rate of 11.1 per second at an intensity of 80 and 90 dB normal hearing level (nHL) using TDH-49 headphones (Telephonics Corp., Farmingdale, NY). A normal ABR was determined by the examination of absolute latencies of waves I, III, and V and interwave latencies of I to III, III to V, and I to V. The absolute and interwave latencies were classified as normal if they were within Ϯ2 SD of the mean latency values established as normative data at the test facility.
waves I to V and generally dysmorphic wave formation. ABRs had normal latencies for waves I to V in three patients (Cases 3, 7, and 8) and prolonged or absent waves in five cases (Cases 1, 2, 4, 5, and 6). At a stimulus intensity of 90 dB nHL, wave I was identifiable in eight of eight cases. Wave III was recorded in all of the cases but was delayed in one of eight cases (Case 4). Wave V showed the greatest abnormalities and was absent in two of eight of all the cases (Cases 1 and 6) and delayed in three of eight cases (Cases 2, 4, and 5) (see the table). The morphology was abnormal in all patients, with markedly reduced peakto-peak amplitudes and wave V/I amplitude ratio reversal (figure 2).
Final assessment. Peripheral hearing was normal in all of the subjects at the time of recording. ABRs after 1 to 3 years showed a clear deterioration in all cases, with worsening morphology leading to extinction of waves; where discernible, waves III and V became delayed (see the table). Wave I was present in all eight of eight cases, wave III was absent in five of eight cases (Cases 1, 4, 5, 6, and 8), and wave V absent in four of eight cases (Cases 1, 4, 5, and 6).
Discussion. Our data lead us to conclude that ERT does not prevent ABR deterioration in GD3 children. Although our sample is small, these data are significantly different from other studies. 5 The reason for this discrepancy is not clear. One possibility may reflect different testing techniques and interpretation. Unfortunately, previous studies [5] [6] [7] have not published waveforms or recording techniques, so we cannot draw further conclusions. In this regard, we have presented examples of our raw ABR data and their interpretations in figure 2 for future comparison. The second possibility is that there are significant genetic differences in patient groups. In our patients, 15 of 16 alleles were the L444P mutation, which is the most common type 3 mutant allele. In another study, 5 26 of 42 were L444P homozygote, 2 of 42 L444P heterozygote, and 14 of 42 unknown.
ABR waveforms reflect the synchronous neural activity in the brainstem auditory pathways, including the eighth cranial nerve, cochlear nucleus, superior olivary complex, lateral lemniscus, or inferior colliculus. Because the exact generator sites of the ABR are unknown, the pathophysiology of abnormalities is speculative. Neuronopathic GD is known to involve the brainstem. 8, 9 Thus, it seems most likely that the progressive deterioration in ABRs reflects underlying subclinical brainstem degeneration in our patients. However, the relationship of the brainstem involvement to CNS progression remains unclear.
Although it is possible that some of these abnormalities could be consistent with a single lesion in the dorsomedial brainstem in and around the saccadic eye movement centers, it is more likely that there are additional lesions, possibly affecting eighth nerve function. 3 We have recently proposed that there is a link between the ocular motor and auditory abnormalities in neuronopathic GD that can be traced to a potentiation for excitotoxicity from excitatory amino acids, most likely glutamate, which is further exacerbated by high average neuronal firing rates in ocular motor and auditory systems. 3 Further study is needed to clarify the origins of these abnormalities.
We cannot exclude the possibility that some GD3 patients may have a more positive response to ERT, but caution is needed as lack of ABR deterioration may simply reflect slower neurologic progression in some patients. We will continue to closely monitor this cohort. The insidious nature of the neurologic disease may mean that outcome measures of the efficacy of ERT or any other treatment for neuronopathic disease may require years of follow-up. Our data emphasize the urgent need to understand the neurotoxic mechanisms in neuronopathic GD to find an alternative treatment. 
